What condition is Tedizolid (Sivextro) effective against?

Tedizolid (Sivextro) is primarily indicated for the treatment of acute bacterial skin and skin structure infections, and it has a specific effectiveness against certain resistant bacterial strains. Among those, it is particularly noted for its activity against Vancomycin-resistant Enterococcus (VRE). This is significant because VRE poses a challenge in treatment due to its resistance to commonly used antibiotics, including vancomycin.

Tedizolid operates as an oxazolidinone antibiotic, offering a different mechanism of action that can overcome the resistance mechanisms that render other antibiotics ineffective against VRE. The ability of Tedizolid to target and treat infections caused by VRE makes it an important option in the antibiotic armamentarium for physicians dealing with multi-drug resistant organisms.

This understanding is crucial when considering the context of the other choices. While E. coli, Streptococcus pneumoniae, and Staphylococcus aureus are important pathogens, Tedizolid is not specifically indicated as a first-line treatment for these infections, especially when compared to its established role in tackling VRE. Thus, its targeted effectiveness against resistant strains like VRE sets it apart as the correct choice in this scenario.